Cellegy renegotiates Tostrex EU license, distribution agreement with ProStrakan

By Lisa Kerner

Erie, Pa., Jan. 19 - Cellegy Pharmaceuticals, Inc. has renegotiated its E.U. license and distribution agreement for its product, Tostrex, with its licensee, ProStrakan Group plc.

Tostrex is a 2% topical testosterone gel for the treatment of male hypogonadism.

Under the terms of the amended agreement, ProStrakan will assume responsibility for all manufacturing and product support functions. ProStrakan will now purchase the product directly from the manufacturer rather than from Cellegy.

Cellegy will continue to receive milestones and royalties as set forth in the original agreement.

Cellegy and ProStrakan, in July 2004, entered into an exclusive license agreement for the commercialization of Tostrex (branded Fortigel in the United States) in Europe.

In September 2005 the product was launched in Sweden by ProStrakan.

ProStrakan will be applying for further approvals of Tostrex throughout the European Union, under the Mutual Recognition Procedure.

Cellegy Pharmaceuticals is a specialty biopharmaceutical company based in Huntingdon Valley, Pa., that develops and commercializes prescription drugs for the treatment of women's health care conditions.

ProStrakan is a specialty pharmaceutical company with its headquarters in Galashiels, Scotland.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.